- Alzheimer’s is the most ominous and expensive disease in the U.S.
- IGC is the first and only NYSE MKT-listed pharmaceutical company to develop cannabis-based Alzheimer’s therapies
- IGC’s patent pending phytocannabinoid therapies to enter clinical trials for potential Alzheimer’s breakthrough
A pioneer in the development of innovative cannabis-based combination therapies, India Globalization Capital (NYSE MKT: IGC) is creating new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patent pending therapeutics include treatments for pain, cachexia, neurologic disorders, Parkinson’s and Alzheimer’s disease. IGC plans to enter clinical trials this year on its primary pipeline of four major therapeutics that address large market maladies. These trials include a potential cannabis-based blockbuster treatment for Alzheimer’s, America’s most ominous and expensive disease.
Alzheimer’s disease has no cure, no means of prevention and no long-term disease-modifying treatments. It’s a fatal, progressive brain disease that slowly destroys memory and thinking skills. It’s the third-leading cause of death in the U.S., following cancer and heart disease. More than 5.3 million Americans and over 46 million people worldwide are currently suffering from Alzheimer’s, and, frighteningly, this number is expected to triple within a few decades. Alzheimer’s is also the most expensive disease in the nation. In 2016, costs totaled $236 billion for the U.S., and global costs exceeded $600 billion. These figures will skyrocket if the disease continues unchecked.
Bolstering its portfolio of patent pending cannabis-based pharmaceuticals, IGC recently acquired exclusive rights to a novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). Under the definitive license agreement with the university, IGC is the exclusive licensee of a patent filing for the use of tetrahydrocannabinol (THC) as a potential therapeutic agent for Alzheimer’s. The patent claims discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.
This new pathway holds immense potential in treating Alzheimer’s, and IGC will own the rights to this unprecedented therapeutic pathway if the patent is granted and proven. Acquiring this patent further supports IGC in protecting its proprietary formulation IGC-AD1, which includes low-doses of THC and is intended to disrupt the buildup of amyloid beta plaques and alleviate some of the worst symptoms of Alzheimer’s disease.
Several clinical studies are currently underway to address the ravages of Alzheimer’s, but later this year IGC will become the first and only company to utilize cannabis-based therapies for the treatment of the disease. Even though there are about a dozen publicly traded cannabis pharmaceutical stocks on the market, none have patent filings to a potential Alzheimer’s breakthrough.
Should IGC’s clinical studies show promise on Alzheimer’s or any of its primary pipeline of phytocannabinoid therapeutics, it could not only trigger a major shift in national medical marijuana policy but also dramatically impact the company’s market capitalization and stock price to the upside.
For more information, please visit http://www.igcinc.us
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
